RAIN - Rain Therapeutics In...

Free Cash Flow of Rain Therapeutics Inc.(RAIN), Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies

Rain Therapeutics Inc.

RAIN

NASDAQ

Inactive Equity

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

1.21 USD

-0.02 (-1.65%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Operating Data Balance Sheet Free Cash Flow Free Cash Flow Buildup Terminal Value Intrinsic Value WACC

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.